Treatment of Focal Ischaemia in Rats with Lubeluzole

Cerebrovascular Diseases

Volumn 7, Issue , 1997, Pages 31-34

  Grotta, James C ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Focal ischaemia; Lubeluzole; Middle cerebral artery occlusion; Neuroprotection; Photothrombotic stroke; Thrombolysis

Indexed keywords

LUBELUZOLE; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; DRUG EFFICACY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; STROKE; TIME;

EID: 0031040448     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000108240     Document Type: Article

References (12)

1. National Institutes of Health recombinant tissue plasminogen activator study. The National Institute of Neurological Disorders and Stroke r-TPA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995:33; 1581 - 1587.
2. Aronowski J, Waxham MN, Grotta JC: Neuronal protection and preservation of calcium/ calmodulin-dependent protein kinase II and protein kinase C activity by dcxtrorphan treatment in global ischaemia. J Ccreb Blood Flow Metab 1992:13:550-557.
3. Grotta JC, Pettigrew LC, Rosenbaum D, Reid C, Rhoades H, McCandless D: Efficacy and mechanism of action of calcium channel blocker alter global cerebral ischaemia in rats. Stroke 1988:19:447-454.
4. Grotta JC. Piconc CM. Ostrow PT. Strong RA. Earls RM. Yao LP. Rhoades HM. Dednian JR: CGS-I9755, a competitive NMDA receptor antagonist, reduces calcium-calmodulin binding and improves outcome after global cerebral ischemia. Ann Neurol 1990;27:612-619.
5. Hara H. Onodera H. Yoshidomi M. Matsuda Y. Kyuya K: Slaurosporine, a novel protein kinase C inhibitor, prevents postischcmic neuronal damage in the gcrbil and rat. J Ccreb Blood Flow Metab 1990:10:646-653.
6. Ozyurt E. Graham DI. Woodruff GN. McCul-loch J: Protective effect of the glutamate antagonist MK-801 in focal cerebral ischaemia in the cat. J Cercb Blood Flow Metab 1988:8:138-143.
7. Diencr H-C, Hacke W, Hcnncrici M, Râdberg J, Hantson L, De Kcyscr J for the Lubeluzole International Study Group: Lubeluzole in acute ischemic stroke. A double-blind, placebo-controlled phase II trial. Stroke 1996;27(1):76-81.
8. De Ryck M, Keersmaekers R, Clincke G, Janssen M, Van Reel S: Lubeluzole, a novel benzothiazolc, protects neurologic function after cerebral thrombotic stroke in rats: An apparent stereospccific effect. Soc Ncurosci Abstr 1994;20:198.
9. De Ryck M. Schellcr D, Clincke G, Janssen M, Van Rcct S: Lubeluzole. a novel benzothiazolc, protects neurologic function, reduces infarct size, and blocks peri-infarct glutamate rise after cerebral thrombotic stroke in rats. Cerebrovasc Res Abstr 1995:5:264.
10. Aronowski J, Strong R, Grotta JC: Treatment of experimental focal ischemia in rats with lubeluzole. Ncuropharmacology 1996:35:689 - 693.
11. Aronowski J. Strong R. Grotta J: Combined ncuroprotcction and repcrfusion therapy for stroke - effect of lubeluzole and diaspirin cross-linked hemoglobin in experimental focal ischemia. Stroke 1996;27:1571-1577.
12. Aronowski J, Ostrow P, Samways E, Strong R. Zivin J, Grotta J: Graded Biassay for demonstration of brain rescue from experimental acute ischemia in rats. Stroke 1994;25:2235-2240